Serum pentraxin-3 as a potential biomarker for liver cancer
Author Information
Author(s): Chen Li, Song Shifu, Chen Mao, Liu Qin, Zhou Hongchi
Primary Institution: The First Affiliated Hospital of Chengdu Medical College
Hypothesis
This study aimed to examine serum pentraxin 3 levels in patients with primary liver cancer and to assess its potential as a diagnostic and prognostic biomarker.
Conclusion
Serum PTX3 levels are elevated in patients with primary liver cancer and high serum PTX3 levels are associated with poor prognosis.
Supporting Evidence
- Serum PTX3 levels were significantly higher in liver cancer patients compared to healthy controls.
- PTX3 effectively differentiated liver cancer patients from healthy controls with an AUC of 0.734.
- Patients with higher PTX3 levels had lower overall survival and recurrence-free survival rates.
Takeaway
Doctors found that a substance called PTX3 in the blood can help tell if someone has liver cancer and how serious it might be.
Methodology
The study measured serum PTX3 levels in 180 liver cancer patients and 180 healthy controls using an ELISA kit and analyzed correlations with clinical characteristics.
Potential Biases
Selection bias could not be entirely eliminated despite using stratification and matching.
Limitations
The sample size was relatively small and limited to the Chinese population, which may affect generalizability.
Participant Demographics
The study included 180 patients with primary liver cancer, consisting of 145 with hepatocellular carcinoma and 35 with intrahepatic cholangiocarcinoma.
Statistical Information
P-Value
0.002
Confidence Interval
95% CI: 0.531–0.892
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website